Related Experiment Videos
Evolving chemotherapy for advanced gastric cancer
1University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA. jajani@mdanderson.org
The Oncologist
|December 22, 2005
Summary
Advanced gastric cancer treatment options are improving with combination chemotherapy, showing significant advantages over supportive care. Newer agents like irinotecan and docetaxel offer promising developments for patients with poor prognoses.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Gastric cancer is a leading cause of cancer death globally.
- Despite surgery, high relapse rates necessitate effective palliative chemotherapy.
Purpose of the Study:
- To review advancements in palliative chemotherapy for advanced gastric cancer.
- To highlight the efficacy of newer chemotherapeutic agents.
Main Methods:
- Review of phase II and III clinical studies.
- Analysis of treatment outcomes with novel agents such as irinotecan, docetaxel, capecitabine, S-1, and oxaliplatin.
Main Results:
- Combination chemotherapy significantly improves outcomes compared to best supportive care.
- Newer agents show promising results in phase II and III trials for advanced gastric cancer.
Conclusions:
- While no single regimen is universally superior, newer agents represent positive developments.
- Palliative chemotherapy remains crucial for improving the prognosis of advanced gastric cancer patients.